Skip to content Skip to sidebar Skip to footer
0 items - $0.00 0

Pharmacological Treatment

HomePharmacological Treatment
Close

Pharmacological Treatment of Parkinson’s Disease

A comprehensive, evidence-based guide to the pharmacological management of Parkinson’s disease — from first-line dopaminergic therapies to advanced device-aided treatments — incorporating the latest international guidelines.

9.1 Principles of Pharmacological Management

Pharmacological therapy in PD is symptomatic, not disease-modifying — current medications reduce symptoms and improve quality of life but do not slow or halt underlying neurodegeneration. The goal of treatment is to optimize motor and non-motor function while minimizing side effects, maintaining this balance across all disease stages. Treatment decisions must be individualized based on: age, disease severity and dominant features, comorbidities, lifestyle priorities, employment status, and the patient’s and caregiver’s values (Fox et al., 2018, JAMA Neurology).

9.2 Levodopa — The Gold Standard

Levodopa (L-3,4-dihydroxyphenylalanine) remains the most effective symptomatic treatment for PD, more than five decades after its introduction by George Cotzias (1968, New England Journal of Medicine). Levodopa crosses the blood-brain barrier and is converted to dopamine by aromatic amino acid decarboxylase (AADC) in the striatum and remaining dopaminergic neurons.

Levodopa is always combined with a peripheral decarboxylase inhibitor — carbidopa (in North America and much of the world) or benserazide (in Europe) — to prevent peripheral conversion, reduce nausea, and allow lower effective doses. Standard formulations include immediate-release (IR) and controlled-release (CR) preparations; the latter provide smoother plasma levels but have variable and unpredictable bioavailability.

Long-term complications of levodopa therapy (typically emerging after 5–10 years) include:

  • Motor fluctuations: “Wearing off” (return of symptoms before next dose), “on-off” fluctuations (sudden, unpredictable transitions between mobile “on” and immobile “off” states)
  • Dyskinesias: Involuntary choreiform or dystonic movements occurring at peak plasma levodopa levels, or at the beginning/end of dose
  • Diphasic dyskinesias: Occurring during the rising and falling phases of levodopa; particularly disabling

9.3 Dopamine Agonists

Dopamine agonists directly stimulate dopamine receptors in the striatum, bypassing the degenerating presynaptic nigrostriatal pathway. They have a longer half-life than levodopa, providing smoother stimulation and fewer motor fluctuations. Non-ergot agonists (pramipexole, ropinirole, rotigotine transdermal patch, apomorphine) are preferred due to the ergot-related side effects (cardiac fibrosis, pleural/retroperitoneal fibrosis) of older compounds (bromocriptine, pergolide).

Dopamine agonists are appropriate first-line therapy in younger patients (<70 years) to delay levodopa initiation and reduce long-term dyskinesia risk. Key side effects include: nausea, orthostatic hypotension, somnolence (including sudden sleep attacks), hallucinations (more common than with levodopa), and impulse control disorders (pathological gambling, hypersexuality, binge eating, compulsive shopping) in 10–20% of patients — requiring regular monitoring and prompt dose reduction or switch if identified.

9.4 MAO-B Inhibitors

Monoamine oxidase type B (MAO-B) inhibitors — selegiline, rasagiline, and safinamide — block the enzymatic breakdown of dopamine in the synapse, extending its action. They can be used as monotherapy in early disease or as adjuncts to levodopa to reduce “off” time. Rasagiline demonstrated a trend toward disease modification in the ADAGIO trial, though this was not confirmed in subsequent analyses. Safinamide has dual mechanisms (MAO-B inhibition and glutamate release modulation), offering additional anti-dyskinetic properties (Borgohain et al., 2014, JAMA Neurology).

9.5 COMT Inhibitors

Catechol-O-methyltransferase (COMT) inhibitors — entacapone, tolcapone, and opicapone — extend levodopa’s half-life by blocking peripheral and central COMT-mediated methylation. They are adjuncts to levodopa/carbidopa in patients with motor fluctuations, reducing “off” time by 1–2 hours daily. Opicapone (once-daily) and entacapone (with each levodopa dose) are the most widely used. Tolcapone requires liver function monitoring due to rare hepatotoxicity. COMT inhibitors may worsen dyskinesias by increasing levodopa bioavailability; concurrent levodopa dose reduction is often needed.

9.6 Amantadine

Amantadine, originally an antiviral, has both dopaminergic and NMDA receptor antagonist properties. Standard immediate-release amantadine provides modest symptomatic benefit in early PD. Extended-release amantadine (Gocovri, Osmolex ER) has FDA approval for dyskinesia treatment — the first oral medication specifically approved for this indication — based on robust RCT evidence showing ~25% reduction in dyskinesia duration and severity (Pahwa et al., 2017, JAMA Neurology). Amantadine also reduces freezing of gait. Side effects include livedo reticularis, ankle edema, hallucinations, and cognitive impairment. Must be tapered slowly due to severe deterioration upon abrupt discontinuation.

9.7 Advanced Device-Aided Therapies

For patients with refractory motor fluctuations inadequately controlled by optimized oral therapy, three device-aided options are available:

  • Deep Brain Stimulation (DBS): See Chapter 10 (Surgical Treatment). The most established advanced therapy.
  • Levodopa-carbidopa intestinal gel (LCIG / Duodopa): Continuous intraduodenal infusion via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube, providing stable plasma levodopa levels 24 hours/day. Reduces “off” time by ~2 hours/day vs. optimized oral therapy. Main complications include PEG-J-related issues (tube displacement, peritonitis, neuropathy) (Olanow et al., 2014, JAMA Neurology).
  • Continuous subcutaneous apomorphine infusion: Subcutaneous pump delivering apomorphine throughout the day. Highly effective for motor fluctuations; avoids surgical risks. Main limitations: skin nodules at infusion sites, frequent monitoring requirements, psychiatric side effects.

9.8 Treatment of Non-Motor Symptoms

Non-motor symptom management requires a multidisciplinary approach. Key pharmacological interventions include:

  • Depression/anxiety: SSRIs and SNRIs are first-line; evidence base is limited compared to general population. TCAs effective but poorly tolerated in elderly.
  • PD psychosis/hallucinations: First reduce/eliminate potentially causative medications (anticholinergics, amantadine, dopamine agonists, selegiline). If treatment needed: clozapine (most effective; requires blood monitoring) or pimavanserin (FDA-approved; 5-HT2A inverse agonist; no motor worsening).
  • PD dementia: Rivastigmine (cholinesterase inhibitor) is the only drug with EMA/FDA approval for PD dementia; modest cognitive benefits (Emre et al., 2004, NEJM). Donepezil and galantamine may also provide benefit.
  • Orthostatic hypotension: Fludrocortisone, midodrine, droxidopa (FDA-approved specifically for PD-related OH).
  • RBD: Melatonin (first-line; safe) or low-dose clonazepam (risk of cognitive worsening, falls).
  • Sialorrhea: Botulinum toxin injections into parotid/submandibular glands; glycopyrrolate sublingual; ipratropium spray.
  • Constipation: Macrogol (polyethylene glycol); prucalopride; dietary fiber and hydration.

References: Borgohain et al. (2014) JAMA Neurology; Emre et al. (2004) NEJM; Fox et al. (2018) JAMA Neurology; Olanow et al. (2014) JAMA Neurology; Pahwa et al. (2017) JAMA Neurology.

Navigation: ← Natural Treatments | Surgical Treatment →